Table 1.
Summary of included studies.
| References | Number of participants (I/C) | Age (y), median (range) I C | Sex(M/F) I C | Disease stage | Median duration of follow-up | Intervention | Regimen (I) | Comparison | Regimen (C) | Initial Plt (×109/L) median (range) I C | Outcomes | Relapse | Grade 3–4 of AEs | 6 months | 12 months | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Din et al. (11) | 61/29 | 29.7 (16–62) | 29 (16–64) | 27/34 | 13/16 | Newly-Diagnosed | 12 months | DXM | 40 mg/day*4 day | PNS | 1 mg/kg ×4 w | 1.1 (10–1.9) | 1.1 (10–1.8) | CR PR OR SR Aes Relapse | 23/13 | 7/0 | ||
| Matschke et al. (12) | 13/9 | 46 (22–77) | 43 (29–65) | 4/9 | 5/4 | Newly-Diagnosed | 12 months | DXM | PNS 1 mg/kg × 1w–> Dex 0.6 mg/kg × 4 d ×6 | PNS | 1 mg/kg × 2w | 2 (0–12) | 5 (1–20) | 3/7 | 2/1 | 11/3 | 10/2 | |
| Praituan and Rojnuckarin (13) | 18/18 | 44.9 (25–64) | 39.5 (24–55) | 5/13 | 3/15 | Newly-Diagnosed | 6 months | DXM | 40 mg/day*4 day | PNS | 1 mg/kg/day*28 day | 8.5 (0–17.2) | 10.3 (1.8–18.8) | |||||
| Mashhadi et al. (14) | 31/31 | 24.9 (17–44) | 27.2 (18–48) | 24/6 | 23/7 | Newly-Diagnosed | 12 months | DXM | 40 mg/day*4 day | PNS | 1 mg/kg/day*28 day | 13.9 (3.4–18) | 10.4 (1.5–16.4) | 3/10 | 1/2 | 27/16 | 27/14 | |
| Sakamoto (15) | 31/69 | 55 (18–86) | 61 (18–91) | 16/15 | 30/39 | Newly-Diagnosed | 12 months | DXM | 40 mg/day*4day | PNS | 0.5–1 mg/kg/day 2–4 w | 8 | 10 | 17/16 | 11/14 | 13/18 | ||
| Wei et al. (16) | 95/97 | 43 (18–73) | 44 (18–75) | 64/31 | 72/25 | Newly-Diagnosed | 24 months | DXM | 40 mg/day*4 day | PNS | 1 mg/kg/day*28 day | 7 (0–29) | 8 (0–36) | 37/32 | 26/38 | 40/45 | 37/32 | |
| Bae et al. (17) | 76/75 | 44 | 20/56 | 26/49 | Newly-Diagnosed | 48 months | DXM | 40 mg/day*4 day | PNS | 1 mg/kg/day*28 day | 16 | 17 | ||||||
| Cui (18) | 30/29 | 31 (16–62) | 34 (18–65) | 12/18 | 10/19 | Newly-Diagnosed | 3 months | DXM | 40 mg/day*4 day | PNS | 1–1.5 mg/kg × 4 w | 10 (0–31) | 12 (3–27) | |||||
| Li et al. (19) | 45/49 | 37 (19–70) | 35 (18–69) | 18/27 | 20/29 | Newly-Diagnosed | 12 months | DXM | 40 mg/day*4 day | PNS | 1.5 mg/kg × 2–4 w | 12 (4–23) | 11 (2–19) | 23/17 | 10/17 | |||
| Nyein et al. (20) | 35/35 | 28.6 (15–42) | 30/40 | Newly-Diagnosed | 6 months | DXM | 40mg/day*4 day | PNS | 1.0 mg/kg BW daily for 4 weeks | ND | ND | |||||||
| Gomez-Almaguer et al. (21) | 20/21 | 43 (16–83) | 51 (18–82) | 15/5 | 17/4 | Newly-Diagnosed | 33 months | DXM | 40 mg/day*4 day | DXM + RTX | RTX 100 mg × 4 w –> Dex 40 mg × 4 d | 13 (9) | 7 (7) | 3/10 | 0/0 | 17/16 | 17/16 | |
| Gudbrandsdottir et al. (22) | 71/62 | 58 (41–70) | 51 (36–63) | 37/34 | 12/36 | Newly-Diagnosed | 38 months | DXM | 40 mg/day*4 day | DXM + RTX | RTX 375 mg/m2 × 4 w –> Dex 40 mg × 4 d | 14 (8–23) | 13 (6–20) | 41/25 | 18/27 | 22/34 | 17/28 | |
| Li et al. (23) | 31/31 | 24 (18–59) | 26 (18–51) | 12/19 | 13/18 | Newly-Diagnosed | 12 months | DXM | 40 mg/day*4 day | DXM + RTX | RTX 100 mg × 4 w –> Dex 40 mg × 4 d | 6 (1–19) | 7 (1–17) | 12/6 | 0/0 | 12/22 | ||
| Zaja (24) | 52/49 | 47 (28–66) | 49 (33–65) | 19/33 | 22/27 | Newly-Diagnosed | 36 months | DXM | 40 mg/day* 4day | DXM + RTX | RTX 375 mg/m2 × 4 w –> Dex 40 mg × 4 d | <20 | ND | 3/7 | 1/5 | 19/31 | ||
| Li et al. (19) | 45/44 | 37 (19–70) | 36 (20–68) | 18/27 | 17/27 | Newly-Diagnosed | 12 months | DXM | 40 mg/day*4 day | DXM+RTX | Dex 40 mg × 4 d –> RTX 100 mg × 4 w | 12 (4–23) | 10 (3–25) | 23/13 | 10/28 | |||
| Cui (25) | 47/48 | 42 (18–70) | 41 (18–70) | 19/28 | 21/27 | Newly-Diagnosed | 6 months | DXM | 12.5 ~ 25 mg, bid ~ qid,1 ~ 4 d | DXM+RTX | RTX100mg, weekly, 28 d –> DXM12.5 ~ 25 mg, bid ~ qid,1 ~ 4 d | 18 (15.4–20.6) | 18 (15.1–20.9) | 22/11 | ||||
RTX, rituximab; DXM, dexamethasone; M, male; F, female; qid, once a day; bid, twice a day; qid four times a day; CR, complete response (platelet count ≥100 × 109/L); PR, partial response (platelet count ≥30 × 109/L); OR, overall response (OR = CR + PR); SR, sustained response (platelet count ≥50 × 109/L at month 6); ND, no determined.